Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

Authors

Volkman HR[a], de Munter L[b], Nguyen JL[a], Tran TMP[b], Mitratza M[b], Marques C[a], Choi L[a], Valluri S[a], Yang J[a], Antón A[c], Casas I[d], Conde-Sousa E[b], Drikite L[b], Grüner B[e], Icardi G[f], Luit ten Kate G[g], Martin C[h], Mira-Iglesias A[i,j], Orrico-Sánchez A[i,j,k], Otero-Romero S[l,m], Rohde G[n], Jodar L[a], McLaughlin JM[a], Bollaerts K[b].

Affiliations

[a]Pfizer Inc., 66 Hudson Blvd. E., New York, NY 10001, United States

[b]P95 Clinical and Epidemiology Services, Diestsevest 125, 3000 Leuven, Belgium

[c]Microbiology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Paseo del Valle de Hebrón 119-129, Barcelona 08035, Spain

[d]Hospital Universitari Germans Trias i Pujol, Carretera del Canyet, Badalona, Barcelona 08916, Spain

[e]University Hospital Ulm, Division of Infectious Diseases, Department of Internal Medicine III, Alber-Einstein-Allee 23, Ulm 89081, Germany

[f]Centro Interuniversitario per la Ricerca sull'Influenza e le altre Infezioni Trasmissibili - IRCCS Policlinico San Martino Hospital, Largo Benzi 10, Genoa 16132, Italy

[g]Universitair Ziekenhuis Antwerpen, Drie Eikenstraat 655, Edegem 2650, Belgium

[h]Le Centre Hospitalier Universitaire St Pierre, Rue Haute 322, Brussels 1000, Belgium

[i]Vaccine Research Department, Fisabio – Public Health, Avda. Cataluña 21, Valencia 46020, Spain

[j]Biomedical Research Consortium of Epidemiology and Public Health (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain

[k]Catholic University of Valencia, Carrer de Quevedo 2, Valencia 46001, Spain

[l]Preventive Medicine and Epidemiology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Paseo del Valle de Hebrón 119-129, Barcelona 08035, Spain

[m]Centro de Esclerosis Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Paseo del Valle de Hebrón 119-129, Barcelona 08035, Spain

[n]Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of Respiratory Medicine, Theodor-Stern-Kai 7, Frankfurt/Main 60590, Germany

Correspondence

Hannah R Volkman, Pfizer – hannah.volkman@pfizer.com

Keywords

SARS-CoV-2; COVID-19; COVID-19 Vaccination; Vaccine effectiveness; BNT162b2; XBB-adapted vaccine; JN.1

Abstract

Background: While multiple studies have shown that the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (BNT162b2 XBB vaccine) is effective in preventing COVID-19 hospitalisation and death, effectiveness beyond six months remains unexplored.

Aim: We extended our previous study of BNT162b2 XBB vaccine effectiveness (VE) to evaluate durability against JN.1-related hospitalisation up to 46 weeks since dose using the id.DRIVE platform across Belgium, Germany, Italy, and Spain.

Methods: This multi-country, multi-centre test-negative case-control study assessed the effectiveness and durability of the BNT162b2 XBB vaccine in preventing JN.1-associated hospitalisation among adults with severe acute respiratory infection between October 2023 and August 2024. Each case was matched with up to four controls by symptom onset date and study site. Multivariable analyses were adjusted for symptom onset date, age, sex, number of chronic conditions, and influenza vaccination receipt.

Results: Among 827 test-positive cases and 2232 test-negative controls, protection against hospitalisation was sustained from 2 to <30 weeks since dose, with evidence of significant waning thereafter. VE was 64.5% (95% CI: 56.6; 71.0) at 2 to <30 weeks, and 4.9% (95% CI: -30.3; 30.7) at 30 to <46 weeks.

Conclusions: Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalization for up to 30 weeks, but protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and/or waning immunity. Given the high COVID-19 activity in Europe during summer 2024, an additional vaccination

after six months is warranted for those at risk of COVID-19 hospitalisation to maintain year-round protection.

Introduction

Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [1], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [2-20]. These studies collectively show that the BNT162b2 XBB vaccine is effective against severe endpoints such as hospitalisation [2-5, 8, 9, 11, 12, 15-18], ICU admission [4], and death [3, 17]. However, its effectiveness in preventing hospitalisation is likely lower against Omicron subvariant JN.1 than XBB (VE of 61%-76% during XBB predominance and VE of 35%-54% during JN.1 predominance) [2-5, 9, 11, 12, 17].

Despite this broad evidence base, the long-term durability of XBB-adapted COVID-19 vaccines beyond 6 months since dose remains unknown. This gap in evidence on long-term effectiveness is especially relevant considering that from June–August 2024, many countries in Europe and around the globe experienced an increase in COVID-19 hospitalisations [21], long after Northern Hemisphere autumn/winter-focused COVID-19 vaccination campaigns had concluded. Changes in COVID-19 dynamics, including SARS-CoV-2 strain shifts [22], complex and evolving population immunity [23], and aseasonal/acyclical increases in hospitalisations [24], have continued since the conclusion of the World Health Organization (WHO)-declared global health emergency [25]. Therefore, it is critical for public health decision-makers to have timely information on the long-term durability of COVID-19 vaccines.

Therefore, we sought to extend the study period of our previously published real-world effectiveness analysis of the BNT162b2 XBB vaccine against JN.1-associated hospitalisation across four European countries (Belgium, Germany, Italy, and Spain) [12]. Our previous report indicated that the BNT162b2 XBB vaccine was 54.8% (95% CI: 39.7; 66.0) effective against JN.1-related hospitalisation after a median of 63 days following vaccination, with

no evidence of waning protection through five months [12]. In this analysis, we measured the long-term durability of the BNT162b2 XBB vaccine, both overall and in risk groups, up to 46 weeks post-dose using the id.DRIVE study platform during a period of JN.1 predominance.

Methods

Study design

As previously described in our analysis of BNT162b2 XBB VE through April 2024 [12], id.DRIVE is an ongoing multi-country, multi-centre test-negative case-control study that began in Europe in November 2020. The study aims to estimate VE against COVID-19-related hospitalisations with laboratory confirmation of SARS-CoV-2 infection among patients admitted with severe acute respiratory infections (SARI). The id.DRIVE Master protocol (EUPAS42328) was approved by independent ethics committees (IECs) at each study site. Patients with SARI were enrolled both prospectively and retrospectively across eight sites, including six hospitals and two hospital networks across Belgium, Germany, Italy, and Spain from 2 October 2023 to 31 August 2024 (**Supplementary Table S1**).

Study objective

The primary objective was to determine the VE and long-term durability of the BNT162b2 XBB vaccine in preventing COVID-19 hospitalisations through 31 August 2024 (up to 46 weeks since dose).

Study participants

Patients included adults aged ≥18 years eligible for COVID-19 vaccination based on national or regional guidelines who were hospitalised for ≥1 night and diagnosed with SARI, based on the European Centre for Disease Prevention and Control (ECDC) case definition [26]. Qualifying SARI symptoms included cough, objective fever (≥38^{0}C), shortness of breath, anosmia, ageusia, or dysgeusia. Symptom onset date must have occurred ≤14 days before hospital admission. Patients were excluded if admitted to

the hospital for COVID-19 within the past 3 months, were incapable of providing a nasopharyngeal or oropharyngeal specimen, or had received a COVID-19 vaccine dose from a manufacturer not authorised by the EMA. Informed consent was obtained from patients or their legal representatives except at study sites where IECs authorised waivers of consent.

SARS-CoV-2 laboratory testing and variant identification

All patients were tested for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) or multiplex PCR between 14 days prior to, and up to 72 hours following, hospital admission. The SARS-CoV-2 infecting strain was further characterised in positive specimens using whole genome sequencing or next-generation sequencing. When sequencing was not possible due to insufficient viral load or poor sample quality, the predominant subvariant present in the country of hospitalisation on symptom onset date was imputed from national reporting sources.

A predominance threshold of ≥70% of sequenced samples was established using country-level genomic reporting by calendar time. Sub-lineages of XBB or JN.1 (such as EG.5, KP.2, and KP.3) were collapsed into their parent lineages. When neither XBB nor JN.1 reached the predominance threshold of ≥70%, the time was classified as a transition period. Country-specific XBB and JN.1 predominance periods are defined in **Supplementary Table S1**.

Exposure and outcome definition

Exposed patients received at least one dose of the BNT162b2 XBB vaccine, irrespective of prior COVID-19 vaccination status, at least 14 days before symptom onset and at least 12 weeks after receipt of any prior COVID-19 vaccine. The unexposed group included patients who did not receive any COVID-19 vaccine during the 2023–2024 season, including never vaccinated patients and those who received COVID-19 vaccines prior to the 2023–2024 season and at least 12 weeks before symptom onset, following national eligibility guidelines [27].

'Test-positive cases' were patients who met the SARI case definition and had at least one positive SARS-CoV-2 result by PCR. 'Test-negative controls' were patients who also met the SARI case definition and received a negative result for all SARS-CoV-2 tests performed.

Data collection and management

COVID-19 vaccination data were collected from registries, medical records, or vaccination cards. Data were collected on age, sex, predefined chronic conditions associated with an increased risk of severe outcomes from SARS-CoV-2 infection (**Supplementary Table S2**), body mass index (BMI), symptom onset date, and clinical course of the hospitalisation. Trained study staff entered data from medical records and patient interviews into an electronic Case Report Form (eCRF, Castor®). Pseudonymised data were transferred to a secure central research server hosted by P95 Clinical and Epidemiology Services (Leuven, Belgium) for analysis.

Statistical methods

Odds ratios (OR) comparing the odds of vaccination between test-positive cases and test-negative controls were estimated using multivariable Generalized Estimating Equation (GEE) logistic regression models. These models accounted for potential intra-cluster correlation among patients from the same study site [28]. The variances associated with ORs were calculated using a robust sandwich estimator, yielding a consistent and asymptotically normal estimator [29]. VE was calculated as (1–OR) × 100%. Models adjusted for symptom onset date, age, sex, number of chronic conditions, and receipt of influenza vaccination in the past 12 months. Each case was matched with up to four controls by study site and 14-day interval from the earliest onset date to minimise potential residual time-varying confounding. Matching was conducted independently for each study objective, using distinct datasets. Calendar time for symptom onset date was modelled using a cubic spline, with the number of knots aligned with the number of symptom onset months included in the analysis. The effect of

age was captured using a cubic spline with two predefined knots at ages 50 and 65 years. When <10% of patients in the dataset were <50 years of age, a single knot at age 65 was used. The cutoff points used to define the age group categories determined the selection of knots for the age effect. To overcome multicollinearity while fitting GEE models, we applied penalisation for spline terms of symptom onset date utilising a modified Penalized GEE (PGEE) package with a ridge penalty term [30].

To estimate VE by time since the last BNT162b2 XBB vaccine dose, the logistic regression model was extended to include the interaction between exposure status and time since the last vaccine dose. The effect of time since the last vaccine dose was captured by a cubic regression spline with a knot at 182 days (or 26 weeks), based on prior evidence of waning VE after 26 weeks for any XBB vaccine [31]. The time-dependent OR was derived on a one-dimensional grid ranging from the minimum to the maximum values of time since the last dose, with a step size of 1 day. The sandwich estimator was used to calculate the variance of the VE by time since the last vaccine dose.

Several sensitivity analyses were performed to assess the robustness of the results obtained from the PGEE approach. These analyses considered different choices regarding the number and location of knots for both symptom onset date and age, the impact of prior COVID-19 infection, and the impact of removing adjustment for influenza vaccination status.

Only patients with complete data on exposure status, SARS-CoV-2 test results, and relevant confounders were included in regression analyses [32]. As 1.6% (113/7223) of the patients with SARI were excluded from analysis due to missing chronic conditions or missing influenza vaccination history (**Figure 2**), the complete case analysis is considered unlikely to produce biased estimates.

Sample size calculations, model specifications, and fitting procedures are provided in the supplementary materials (**Appendix A.1, A.2,** and **A.3**). All analyses were conducted using R version 4.1.2 [33].

Results

Study population

From 2 October 2023 to 31 August 2024, 7223 patients hospitalised with SARI were enrolled. There were 801 patients with symptom onset during XBB predominance or the transition period, and/or with non-JN.1 sequencing results who were excluded. Overall, 6094 (84.4%) patients with a confirmed JN.1 sequencing result or a SARI onset date during the country-specific JN.1 predominance period were eligible for analysis. After matching, a total of 3059 patients were ultimately included (**Supplementary Figure S1**).

Figure 1 indicates an increase in enrolment among patients with SARI overall and among test-positive cases in the winter months, which peaked in late December 2023. A subsequent increase among only test-positive cases peaked again in July 2024, corresponding to the summer increase of COVID-19 observed in Europe [34]. During JN.1 predominance, 77.4% (2368/3059) of all hospitalised patients with SARI were ≥65 years of age, 53.3% (1630/3059) were male, and 41.4% (1266/3059) had ≥3 chronic conditions (**Table 1**). The most prevalent chronic conditions included hypertension (62.4% of total patients), cardiovascular disease (41.9%), lung disease (35.6%), type 2 diabetes (30.4%), and immunodeficiency or cancer (21.2%). The median age of test-positive cases was 78 years (interquartile range [IQR] 66–86), and more than half were male (53.2%, n=440), similar to test-negative controls.

In total, 53.4% (1633/3059) of participants received the BNT162b2 XBB vaccine, including 45.7% (378/827) of test-positive cases and 56.2% (1255/2232) of test-negative controls (**Table 1**). Among the 1426 patients who did not receive a COVID-19 vaccine during the 2023–2024 season, 161 (11.3%)

243 had never been vaccinated, 697 (48.9%) received ≥2 mRNA wildtype doses
244 only, and 379 (26.6%) most recently received an original bivalent BA.4/5-
245 adapted booster. Patients who were not vaccinated during the 2023–2024
246 season tended to be younger compared with those who received the
247 BNT162b2 XBB vaccine (median age 71 years [IQR: 57–82] versus 80 years
248 [IQR: 73–88]) and had fewer chronic conditions (35.3% with ≥3 chronic
249 conditions compared to 46.7%).

250 The median length of hospital stay was 6 days (IQR: 4–9) (**Table 1**). In total,
251 5.9% of patients (181/3059) died in the hospital. One-quarter (24.9%
252 [592/2379]) of patients did not require respiratory support, including 27.9%
253 (167/598) of test-positive cases and 23.9% (425/1781) of test-negative controls.
254 Overall, 62.9% (1497/2379) of patients received oxygen therapy, 11.3%
255 (270/2379) received non-invasive ventilation, and 0.8% (20/2379) received
256 invasive mechanical ventilation or extracorporeal membrane oxygenation
257 (ECMO).

258 COVID-19 vaccine effectiveness

259 The overall effectiveness of the BNT162b2 XBB vaccine against JN.1-related
260 hospitalisation was 47.9% (95% CI: 37.0; 56.9) at a median of 107 (IQR: 65–223)
261 days since dose compared with no COVID-19 vaccination during the 2023–
262 2024 season (**Figure 2**).

263 Effectiveness was higher among patients 18–64 years of age than those ≥65
264 years (65.6% [95% CI: 55.5; 73.5] and 44.9% [95% CI: 39.5; 49.7], respectively). VE
265 was similar when stratified across a broad range of chronic condition
266 groups; however, when considering the number of chronic conditions,
267 patients with 2 chronic conditions had a higher VE than patients with 0–1 or
268 ≥3 chronic conditions. VE was higher against more severe in-hospital
269 endpoints, such as ICU admission or death than hospital admission alone,
270 although confidence intervals overlapped. VE against hospital admission
271 without ICU admission or death was 46.5% (95% CI: 31.9; 58.0). VE against ICU
272 admission or in-hospital death was 55.4% (95% CI: 21.3; 74.8). The sample size
273 was insufficient to estimate VE for the more severe respiratory support

endpoints, such as invasive mechanical ventilation or ECMO. Effectiveness appeared slightly higher against longer hospital stays, although confidence intervals overlapped, with VE against a JN.1-related hospitalisation of ≥2 days was 49.2% (95% CI: 40.7 to 56.4), while VE against a hospitalisation with a length of ≥7 days was 61.5% (95% CI: 51.8; 69.2) (**Figure 2**).

To determine BNT162b2 XBB VE according to prior COVID-19 vaccination status and to discern any potential residual protection from COVID-19 vaccines received before the 2023–2024 season, VE was stratified by distinct comparison groups (**Supplementary Figure S2**). Compared with receiving ≥1 mRNA BA.4/5 original bivalent dose, the BNT162b2 XBB vaccine was 48.6% (95% CI: 38.9; 56.7) effective, similar to the overall estimate that used a comparison group of no vaccine in the 2023–2024 season. When compared with ≥2 mRNA wildtype doses only, VE was also similar to the overall VE estimate at 46.4% (95% CI: 37.1 to 54.4). VE of the BNT162b2 XBB vaccine was lower when only compared to patients never vaccinated against COVID-19 at 26.7% (95% CI: -38.8; 61.3), although wide confidence intervals suggested considerable uncertainty of the point estimate.

Durability

VE stratified by time since BNT162b2 XBB vaccine dose was 64.5% (95% CI: 56.6; 71.0) at 2 to <30 weeks, with a VE of 68.6% (95% CI: 56.0; 77.6) at 2 to <12 weeks, 75.3% (95% CI: 68.4; 80.6) at 12 to <18 weeks, 59.2% (95% CI: 43.9; 70.3) at 18 to <24 weeks, and 50.5% (95% CI: 35.8; 61.9) at 24 to <30 weeks (**Figure 2**). VE at 30 to <46 weeks since BNT162b2 XBB vaccine dose was 4.9% (95% CI: -30.3; 30.7). These stratified results are consistent with estimates from the spline-based approach (**Figure 3**), which indicated a slight increase in VE from approximately 2 to 15 weeks since receipt of the BNT162b2 XBB vaccine, followed by relatively flat VE through 25 weeks, and lastly, a steeper decrease in VE after 25 weeks that reached a central estimate of 0% effectiveness at 33 weeks since dose.

When stratified by age groups and number of chronic conditions (**Figure 4** and **Figure 5**), the durability of the BNT162b2 XBB vaccine followed a waning

305 pattern consistent with the overall trend wherein effectiveness begins
306 decreasing in the 18 to <24 weeks post-dose stratum. Similar results were
307 observed when stratified by level of SARI severity (**Supplementary Figure**
308 **S3**).

309 ### Sensitivity analyses

310 Results of sensitivity analyses that changed the number and location of
311 knots for both symptom onset date and age were comparable to VE
312 estimates obtained in the main analysis. When stratified by prior COVID-19
313 infection status, VE was 39.8% (95% CI: 12.4; 58.6) among patients with
314 documented prior COVID-19 infection and 46.4% (95% CI: 36.0; 55.1) among
315 patients with no documented prior COVID-19 infection (**Supplementary**
316 **Figure S8**).

317 Estimates were lower after removing adjustment for influenza vaccination
318 status; VE was 40.9% (95% CI: 24.3; 53.9) without influenza vaccination status
319 adjustment (**Supplementary Figure S9**) and 47.9% (95% CI: 37.0; 56.9) with
320 influenza vaccination status adjustment (**Figure 2**).

321 Discussion

322 In this test-negative case-control study conducted in the id.DRIVE platform
323 in Europe, the BNT162b2 XBB vaccine was 47.9% (95% CI: 37.0; 56.9) effective
324 at a median of 107 days (IQR: 65; 223) since dose against JN.1-associated
325 hospitalisation. VE peaked at 10–12 weeks since dose, with a decline
326 observed after 15 weeks, and continuing to drop through 24 to <30 weeks
327 since dose, irrespective of age group and comorbidity status. We found no
328 evidence of protection against JN.1-associated hospitalisation beyond 30
329 weeks since dose.

330 The VE patterns observed in this study are consistent with the limited
331 available evidence on the durability of XBB-adapted vaccines. A study
332 conducted in Europe by Nunes and colleagues of primarily BNT162b2 XBB
333 vaccine during JN.1 predominance, found that VE against hospitalisation

334 was 47% (95% CI: 32; 59) for adults aged 65–79 years and 39% (95% CI: 17; 54)
335 for adults aged ≥80 years at 90 to 179 days (~13 to 25.5 weeks) since dose,
336 with no evidence of waning through 25.5 weeks [17]. In our study, we
337 observed a numerically higher VE of 56.4% (95% CI: 34.7; 70.9) at 18 to <24
338 weeks since dose among adults aged ≥65 years, albeit with confidence
339 intervals overlapping that of Nunes et al.

340 Link-Gelles reported VE against hospitalisation up to 43 weeks since dose for
341 any XBB vaccine in the VISION Network in the United States [31]. Among
342 immunocompetent adults aged ≥18 years, VE against COVID-19
343 hospitalisation during XBB and JN.1 predominant periods was 21% (95% CI:
344 10; 31) at 17 to 25.5 weeks since dose. At 26 to 43 weeks, XBB-adapted
345 vaccines no longer provided significant protection against hospitalisation
346 (VE: -8% [95% CI: -19; 3]) [31]. We found a higher VE of 59.2% (95% CI: 43.9; 70.3)
347 at a comparable intermediate timepoint since dose at 18 to <24 weeks.
348 However, minimal to no remaining protection was apparent in either study
349 at the latest time points, >26 or >30 weeks since dose. Together, these
350 findings suggest XBB vaccines may provide limited protection against
351 COVID-19 hospitalisation in the latter 6 months of a once-yearly vaccination
352 schedule.

353 As shown by Shrestha et al. (2024), Tartof et al. (2024), and Caffrey et al.
354 (2024), the effectiveness of the BNT162b2 XBB vaccine was higher during
355 XBB predominance compared to its effectiveness during JN.1 predominance
356 [9-11]. This has also been shown in studies not limited to the BNT162b2
357 vaccine [35, 36]. VE tends to decrease when the circulating SARS-CoV-2
358 strains exhibit significant divergence from the subvariant targeted in the
359 vaccine, supporting the need for periodic updates to variant-adapted
360 COVID-19 vaccines. Nevertheless, we observed that BNT162b2 XBB vaccine
361 was effective against JN.1-associated hospitalisation for up to six months.

362 Our main findings remained consistent across various sensitivity analyses,
363 including modifying the number and location of knots for symptom onset
364 date and age and stratifying by prior COVID-19 infection status. Similar to

365 our first analysis [12], adjusting for influenza vaccination status in the last 12
366 months increased VE estimates. The inclusion of influenza vaccination
367 status as a covariate in adjusted models can reduce potential residual bias
368 related to the likelihood of enrolment as a test-negative control [37].

369 The inclusion of multiple sites across four European countries was a
370 strength of this multi-centre study. This enabled broader surveillance to
371 identify the JN.1 subvariant early, allowing follow-up for up to 46 weeks after
372 XBB vaccination. We determined vaccination status using vaccine registries,
373 vaccination cards, and health records, which likely reduced misclassification
374 of exposure. Patients' case status was verified using PCR which reduced the
375 likelihood of misclassifying cases and controls. Furthermore, utilising the
376 test-negative approach and requiring both cases and controls to be
377 hospitalised with a SARI illness helped to account for unmeasured
378 confounding factors linked to healthcare-seeking behaviours and exposure
379 to respiratory pathogens.

380 Our study is subject to several limitations. Although results from sensitivity
381 analyses were similar to the main results, our study nonetheless could be
382 subject to residual confounding, particularly related to factors that are
383 difficult to accurately measure, such as history of COVID-19 and time since
384 the last infection. While we did collect information on prior infection status,
385 this information was frequently missing, and prior infections are likely
386 underestimated, given known discrepancies in the underreporting of SARS-
387 CoV-2 infections [38]. Overall, 71% of the patients with SARI included in our
388 analysis did not have a documented prior SARS-CoV-2 infection. Second,
389 limited sample size for some stratified analyses prevented VE estimation or
390 reduced the precision of VE estimated for certain in-hospital endpoints,
391 such as the use of respiratory support. There was a high proportion
392 (505/2025; 25%) of missing data for in-hospital respiratory support, which
393 reduced the statistical power. Missingness was most prevalent in patients
394 who did not receive the BNT162b2 XBB vaccine and was equally distributed
395 among unvaccinated test-positive cases and test-negative controls (both

34%). Third, the generalisability of our findings beyond European populations primarily comprised of older adults is unknown.

We found that the effectiveness of the BNT162b2 XBB vaccine waned over time, with no evidence of remaining protection against hospitalisation by about 30 weeks since dose. These findings have important implications for the frequency of COVID-19 vaccination for high-risk patients, such as those with comorbid conditions and older adults. As evidenced by the July–August 2024 summer increase in COVID-19 hospitalisations in Europe, COVID-19 activity remains unpredictable, unlike the seasonal patterns displayed by influenza and some other respiratory viruses. Our findings support the need for additional vaccination in the spring season to maintain year-round protection against constantly changing circulating SARS-CoV-2 strains and unexpected increases in COVID-19 activity.

Statements

Ethical statement

Ethical approval for this study was obtained from Ethisch Comité UZA; Comitato Etico Regionale della Liguria (Genoa); Comité Ético de Investigación con Medicamentos del Departamento de Salud Arnau de Vilanova (Valencia); Comité Ético de Investigación con Medicamentos del Hospital Universitari Vall d'Hebron (Barcelona); Ethikkommission des Fachbereichs Medizin der Goethe-Universität (Frankfurt); Ethikkommission Ulm.

Funding statement

This study was conducted as a collaboration between Pfizer and P95. P95 is the study sponsor. Pfizer was involved in the study design, data collection, data interpretation, and writing of the manuscript.

Data availability

De-identified data that underlie the results reported in this article (text, tables, figures, and appendices) may be obtained in accordance with id.DRIVE data access policy.

Acknowledgements

The authors thank all current and former partners of COVIDRIVE and id.DRIVE (AstraZeneca, Bavarian Nordic, CureVac, FISABIO, GSK, Janssen, Novavax, Moderna, Pfizer, Sanofi, THL, Valneva, and P95) for their contribution to the Partnership.

The authors thank Prof. Elizabeth Miller, a member of the id.DRIVE Independent Scientific Committee, for her valuable scientific advice to the id.DRIVE studies.

The authors thank Pfizer, Novavax, and Valneva for their funding contribution to the data collection of the study reported in this publication.

The authors acknowledge the contribution of Sultan Abduljawad and Shanti Pather of BioNTech.

The authors thank Hospital Universitario Vall d'Hebrón, Hospital Universitari Germans Trias i Pujol, University Hospital Ulm, Centro Interuniversitario per la Ricerca sull'Influenza e le altre Infezioni Trasmissibili, Universitair Ziekenhuis Antwerpen, Le Centre Hospitalier Universitaire St Pierre, Valencia Hospital Network for the Study of Infectious Diseases (VAHNSI)-Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fisabio – Public Health), and University Hospital Frankfurt for collecting data of the study reported in this publication.

The authors wish to acknowledge the contribution of Griet Rebry (study operations), Juan Hernandez (statistician), Somsuvro Basu (medical writer) (all from P95 Clinical and Epidemiology Services), Brenda Marquina Sánchez (coordinator) of FISABIO, and all other members of the id.DRIVE Co-Coordination team.

Conflict of interest

Pfizer Inc. funded this study. HRV, JLN, C Marques, LC, SV, JY, LJ, and JMML are employees of Pfizer Inc. HRV, JLN, LC, SV, JY, LJ, and JMML hold stocks or stock options in Pfizer Inc. EC-S, KB, LD, LdM, MM, and TMPT are employees of P95 Clinical and Epidemiology Services, which received funding from Pfizer in connection with the development of this manuscript. TMPT declares the possibility of owning stock or stock options in P95. KB has received consulting fees from Pfizer Inc. for conducting this study. AOS declares payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from GSK, MSD, and Sanofi. AOS also reports support from GSK, MSD, and Sanofi to their institution for attending meetings and/or travel. IC reports support from Pfizer for congress attendance. AM-I reports being associated with the Fisabio foundation. Fisabio received funding from P95 via id.DRIVE to conduct the study. GR declares being the chairman of the executive board (unpaid) of the CAPNETZ foundation. Furthermore, GR reports personal fees from

AstraZeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis, and Pfizer for consultancy during advisory board meetings and personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer, and Vertex for lectures. SO-R declares consulting fees from Moderna and Sanofi, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK and AstraZeneca. Moreover, SO-R reports support from Pfizer for attending meetings and/or travel. AA, BG, C Martin, EC-S, GI, GLtK, LdM, LD, and MM declare no conflicts of interest.

Authors' contributions

This study was designed by members of the id.DRIVE consortium in collaboration with Pfizer. AA, IC, BG, GI, GLtK, C Martin, AM-I, AOS, SO-R, and GR are principal investigators at the study sites and were responsible for data collection and site coordination. Study site principal investigators gathered the data in collaboration with P95 and Pfizer. LD is involved in the coordination of the id.DRIVE study. All statistical analysis was performed by TMPT and EC-S. The data were interpreted by HRV, LdM, JLN, MM, C Marques, LC, SV, JY, LJ, JMM, and KB. LdM and LD accessed and verified the underlying data in the manuscript. HRV and LdM wrote the first draft of the manuscript. All authors reviewed, provided feedback on the manuscript drafts, and approved the manuscript for submission.

References

1. EMA. Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 2023 [Available from: https://www.ema.europa.eu/en/news/comirnaty-ema-recommends-approval-adapted-covid-19-vaccine-targeting-omicron-xbb15.
2. Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. The Lancet Infectious Diseases. 2024;24(2):e73-e4.
3. Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. Influenza and Other Respiratory Viruses. 2024;18(4):e13292.
4. van Werkhoven CH, Valk A-W, Smagge B, de Melker HE, Knol MJ, Hahné SJ, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Eurosurveillance. 2024;29(1):2300703.
5. Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, et al. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19. JAMA Internal Medicine. 2024;184(8):932-40.
6. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, et al. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024. Vaccine. 2024;42(19):3931-7.
7. Huiberts AJ, Hoeve CE, de Gier B, Cremer J, van der Veer B, de Melker HE, et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Eurosurveillance. 2024;29(10):2400109.
8. UKHSA. COVID-19 vaccine surveillance report (week 17) 2024 [Available from: https://assets.publishing.service.gov.uk/media/662a43ed55e1582b6ca7e5ec/Vaccine_surveillance_report_2024_week_17.pdf.
9. Caffrey AR, Appaneal HJ, Lopes VV, Puzniak L, Zasowski EJ, Jodar L, et al. Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System. Nature Communications. 2024;15(1):9490.
10. Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Effectiveness of the 2023–2024 Formulation of the COVID-19 Messenger RNA Vaccine. Clinical Infectious Diseases. 2024;79(2):405-11.
11. Tartof SY, Slezak JM, Puzniak L, Frankland TB, Ackerson BK, Jodar L, et al. Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages. Open Forum Infectious Diseases. 2024;11(7).
12. Nguyen JL, Mitratza M, Volkman HR, de Munter L, Tran TMP, Marques C, et al. Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform. eClinicalMedicine. 2025;79.
13. Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN.1 Variant. medRxiv. 2024:2024.04.27.24306378.
14. Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, et al. Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024. Influenza and Other Respiratory Viruses. 2024;18(11):e70009.

15. Tartof SY, Frankland TB, Puzniak L, Slezak JM, Ackerson BK, Hong V, et al. BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age. JAMA Network Open. 2024;7(12):e2449944-e.
16. Andersen KM, Allen KE, Nepal RM, Mateus JS, Yu T, Zhou A, et al. Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states. Vaccine. 2025;52:126881.
17. Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study. Expert Review of Vaccines. 2024;23(1):1085-90.
18. UKHSA. COVID-19 vaccine surveillance report (week 29): UKHSA; 2024 [Available from: https://assets.publishing.service.gov.uk/media/669923b20808eaf43b50d1fd/Vaccine_surveillance_report_2024_week_29.pdf.
19. Ward T, Paton RS, Overton CE, Mellor J, Aziz NA, Charlett A, et al. Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey. Journal of Infection.
20. Lin D-Y, Du Y, Xu Y, Paritala S, Donahue M, Maloney P. Effectiveness of XBB.1.5 Vaccines Against Omicron Subvariants. medRxiv. 2024:2024.07.01.24309806.
21. ERVISS. ERVISS Dashboard 2025 [Available from: https://erviss.org/.
22. Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nature Communications. 2024;15(1):2254.
23. Jian F, Wang J, Yisimayi A, Song W, Xu Y, Chen X, et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature. 2024.
24. CDC. COVID-19 can surge throughout the year 2024 [Available from: https://www.cdc.gov/ncird/whats-new/covid-19-can-surge-throughout-the-year.html.
25. WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic 2023 [Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.
26. ECDC. ECDC Technical report: Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0 2021 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf.
27. EMA. EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2 virus variants 2023 [Available from: https://www.ema.europa.eu/en/news/ema-and-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants.
28. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121-30.
30. Inan G, Wang L. PGEE: An R Package for Analysis of Longitudinal Data with High-Dimensional Covariates. The R Journal. 2017;9:393-402.
31. Link-Gelles R. Effectiveness of 2023-2024 COVID-19 vaccines in the United States – VISION Network. [Presentation]. In press 2024.

32. Lee S-Y. Handbook of Latent Variable and Related Models: Elsevier; 2007.
33. R-Core-Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.2021.
34. ECDC. Communicable disease threats report (Week 53; 28 December 2024 – 3 January 2025) 2025 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-53-2024.pdf.
35. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, et al. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases. 2024:ciae405.
36. Carazo S, Skowronski DM, Brousseau N, Guay C-A, Sauvageau C, Racine É, et al. Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up. medRxiv. 2024:2024.11.13.24317190.
37. Doll MK, Pettigrew SM, Ma J, Verma A. Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. Clin Infect Dis. 2022;75(1):e564-e71.
38. Mustapha M, Togo K, Volkman HR, Yang J, Yehoshua A, Fusco MDM, J. M. , et al. Under-Reporting of SARS-CoV-2 Infections in 27 Countries, 2020–2022. SSRN. 2024.

Tables and figures

Figure 1. Number of enrolled patients with SARI according to SARS-CoV-2 case classification over time during XBB predominance, a transition period, and JN.1 predominance: A) overall and B) by country



Table 1. Characteristics of study participants according to receipt of BNT162b2 XBB vaccine and SARS-CoV-2 case classification.

		Received BNT162b2 XBB vaccine in 2023–2024 season, (N, col %)		Did not receive any COVID-19 vaccine in 2023–2024 season, (N, col %)	
	Total, N (col %)	**Test-positive cases**	**Test-negative controls**	**Test-positive cases**	**Test-negative controls**
Total	3059	378	1255	449	977
Prior COVID-19 vaccination					
Never vaccinated	170 (5.6)	2 (0.5)	7 (0.6)	45 (10.0)	116 (11.9)

		Received BNT162b2 XBB vaccine in 2023–2024 season, (N, col %)		Did not receive any COVID-19 vaccine in 2023–2024 season, (N, col %)	
	Total, N (col %)	**Test-positive cases**	**Test-negative controls**	**Test-positive cases**	**Test-negative controls**
≥2 mRNA wildtype doses only	914 (29.9)	54 (14.3)	163 (13.0)	219 (48.8)	478 (48.9)
≥1 mRNA original bivalent BA.4/5 booster	1732 (56.6)	311 (82.3)	1042 (83.0)	134 (29.8)	245 (25.1)
Other[1]	243 (7.9)	11 (2.9)	43 (3.4)	51 (11.4)	138 (14.1)
Sex					
Female	1429 (46.7)	165 (43.7)	594 (47.3)	222 (49.4)	448 (45.9)
Male	1630 (53.3)	213 (56.3)	661 (52.7)	227 (50.6)	529 (54.1)
Age, years					
Median (IQR)	77.0 (66.0, 86.0)	81.0 (73.0, 88.0)	80.0 (72.5, 88.0)	74.0 (60.0, 84.0)	70.0 (56.0, 80.0)
18-49	261 (8.5)	3 (0.8)	19 (1.5)	60 (13.4)	179 (18.3)
50-64	430 (14.1)	32 (8.5)	112 (8.9)	93 (20.7)	193 (19.8)
≥65	2368 (77.4)	343 (90.7)	1124 (89.6)	296 (65.9)	605 (61.9)
Body mass index (BMI)[2], kg/m^2					
Median (IQR)	25.7 (22.8, 29.4)	25.8 (22.8, 29.1)	26.1 (23.0, 30.1)	25.0 (22.6, 29.0)	25.4 (22.7, 29.3)
Underweight (BMI <18.5)	98 (4.2)	15 (4.9)	33 (3.2)	21 (6.6)	29 (4.2)
Normal weight (BMI ≥18.5 to <25.0)	902 (38.4)	115 (37.6)	383 (37.3)	130 (40.8)	274 (39.4)
Overweight (BMI ≥25.0 to <30.0)	752 (32.0)	108 (35.3)	332 (32.3)	89 (27.9)	223 (32.1)
Obese (BMI ≥30.0)[3]	595 (25.4)	68 (22.2)	279 (27.2)	79 (24.8)	169 (24.3)
Missing	712	72	228	130	282
Number of chronic conditions					
0-1[4]	966 (31.6)	103 (27.2)	280 (22.3)	160 (35.6)	423 (43.3)
2	827 (27.0)	95 (25.1)	393 (31.3)	112 (24.9)	227 (23.2)
≥3	1266 (41.4)	180 (47.6)	582 (46.4)	177 (39.4)	327 (33.5)
Type of chronic condition					
Asthma	269 (8.8)	26 (6.9)	113 (9.0)	37 (8.2)	93 (9.5)
Lung disease	1089 (35.6)	125 (33.1)	524 (41.8)	128 (28.5)	312 (31.9)
Cardiovascular disease	1283 (41.9)	170 (45.0)	610 (48.6)	179 (39.9)	324 (33.2)
Hypertension	1908 (62.4)	258 (68.3)	903 (72.0)	258 (57.5)	489 (50.1)
Renal disease	196 (6.4)	25 (6.6)	64 (5.1)	46 (10.2)	61 (6.2)
Liver disease	500 (16.3)	89 (23.5)	208 (16.6)	82 (18.3)	121 (12.4)
Type 2 diabetes	931 (30.4)	137 (36.2)	439 (35.0)	123 (27.4)	232 (23.7)

		Received BNT162b2 XBB vaccine in 2023–2024 season, (N, col %)		Did not receive any COVID-19 vaccine in 2023–2024 season, (N, col %)	
	Total, N (col %)	**Test-positive cases**	**Test-negative controls**	**Test-positive cases**	**Test-negative controls**
Immunodeficiency or cancer[5]	648 (21.2)	93 (24.6)	223 (17.8)	125 (27.8)	207 (21.2)
Reported prior SARS-CoV-2 infection[2]					
Yes	913 (34.7)	124 (36.3)	396 (35.4)	119 (31.6)	274 (34.5)
No	1717 (65.3)	218 (63.7)	722 (64.6)	257 (68.4)	520 (65.5)
Missing	429	36	137	73	183
Influenza vaccination within 12 months prior to hospitalisation					
Yes	1861 (60.8)	358 (94.7)	1195 (95.2)	116 (25.8)	192 (19.7)
No	1198 (39.2)	20 (5.3)	60 (4.8)	333 (74.2)	785 (80.3)
Symptom onset, month					
Nov 2023	4 (0.1)	0 (0.0)	0 (0.0)	4 (0.9)	0 (0.0)
Dec 2023	744 (24.3)	59 (15.6)	300 (23.9)	99 (22.0)	286 (29.3)
Jan 2024	713 (23.3)	59 (15.6)	334 (26.6)	96 (21.4)	224 (22.9)
Feb 2024	183 (6.0)	14 (3.7)	84 (6.7)	24 (5.3)	61 (6.2)
Mar 2024	121 (4.0)	8 (2.1)	55 (4.4)	14 (3.1)	44 (4.5)
Apr 2024	80 (2.6)	10 (2.6)	45 (3.6)	6 (1.3)	19 (1.9)
May 2024	206 (6.7)	21 (5.6)	134 (10.7)	17 (3.8)	34 (3.5)
Jun 2024	384 (12.6)	71 (18.8)	129 (10.3)	69 (15.4)	115 (11.8)
Jul 2024	408 (13.3)	92 (24.3)	108 (8.6)	90 (20.0)	118 (12.1)
Aug 2024	216 (7.1)	44 (11.6)	66 (5.3)	30 (6.7)	76 (7.8)
Country of hospitalisation					
Belgium	5 (0.2)	1 (0.3)	4 (0.3)	0 (0.0)	0 (0.0)
Germany	25 (0.8)	0 (0.0)	1 (0.1)	8 (1.8)	16 (1.6)
Italy	255 (8.3)	15 (4.0)	30 (2.4)	53 (11.8)	157 (16.1)
Spain	2774 (90.7)	362 (95.8)	1220 (97.2)	388 (86.4)	804 (82.3)
Length of hospital stay, days					
Median (IQR)	6.0 (4.0, 9.0)	5.0 (4.0, 8.0)	6.0 (4.0, 9.0)	6.0 (4.0, 10.0)	6.0 (4.0, 10.0)
1–3	650 (21.2)	83 (22.0)	254 (20.2)	90 (20.0)	223 (22.8)
4–6	1082 (35.4)	158 (41.8)	446 (35.5)	162 (36.1)	316 (32.3)
7–13	918 (30.0)	99 (26.2)	410 (32.7)	118 (26.3)	291 (29.8)
14–27	320 (10.5)	30 (7.9)	123 (9.8)	63 (14.0)	104 (10.6)

		Received BNT162b2 XBB vaccine in 2023–2024 season, (N, col %)		Did not receive any COVID-19 vaccine in 2023–2024 season, (N, col %)	
	Total, N (col %)	**Test-positive cases**	**Test-negative controls**	**Test-positive cases**	**Test-negative controls**
28–41	54 (1.8)	7 (1.9)	14 (1.1)	9 (2.0)	24 (2.5)
≥42	35 (1.1)	1 (0.3)	8 (0.6)	7 (1.6)	19 (1.9)
Level of respiratory support[2]					
None	592 (24.9)	69 (23.8)	215 (19.9)	98 (31.8)	210 (29.9)
Oxygen therapy	1497 (62.9)	187 (64.5)	714 (66.2)	187 (60.7)	409 (58.2)
Non-invasive ventilation	270 (11.3)	34 (11.7)	140 (13.0)	19 (6.2)	77 (11.0)
Invasive mechanical ventilation	19 (0.8)	0 (0.0)	9 (0.8)	3 (1.0)	7 (1.0)
ECMO	1 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Missing	680	88	177	141	274
Level of SARI severity[2]					
Hospital admission without ICU admission and without in-hospital death	2793 (91.5)	347 (92.0)	1142 (91.1)	408 (91.3)	896 (91.9)
ICU admission without in-hospital death	79 (2.6)	4 (1.1)	25 (2.0)	15 (3.4)	35 (3.6)
In-hospital death	181 (5.9)	26 (6.9)	87 (6.9)	24 (5.4)	44 (4.5)
Missing	6	1	1	2	2

Abbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; N, number.

[1] "Other" includes the following: mRNA original bivalent BA.1 vaccine, a single mRNA wildtype dose only, a single mRNA wildtype dose following non-mRNA dose(s), ≥2 mRNA wildtype doses following non-mRNA doses, any number of non-mRNA doses.

[2] Percentages exclude study participants with missing values.

[3] Obese classification was based on both BMI ≥30.0 kg/m^2 and obesity as a categorical variable (yes/no).

[4] The categories "0" and "1" among the number of chronic conditions are counted as separate categories of number of chronic conditions, based on the list of chronic conditions provided in Supplementary Table S2. Here, the cell counts among participants having "0–1" chronic conditions are provided as a composite.

[5] The categories "Cancer" and "Immunodeficiency" among chronic conditions are identified as separate types of chronic conditions. Here, the cell counts among participants having "Immunodeficiency or cancer" are provided as a composite.

Figure 2. Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

Strata	Exposure	Total, N	Test-positive cases: N (%)	Test-negative controls: N (%)	Days since last vaccine dose: Median (Q1; Q3)	VE (95% CI)[1]
Overall						
Overall	Yes	1633	378 (23%)	1255 (77%)	107 (65; 223)	47.9% (37.0; 56.9)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
Age group (years)						
18-64y	Yes	166	35 (21%)	131 (79%)	106 (62; 226)	65.6% (55.5; 73.5)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
≥65y	Yes	1467	343 (23%)	1124 (77%)	107 (65; 223)	44.9% (39.5; 49.7)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
65-79y	Yes	589	129 (22%)	460 (78%)	115 (60; 220)	33.1% (-11.3; 59.8)
	No	457	132 (29%)	325 (71%)	724 (533; 873)[2]	
≥80y	Yes	878	214 (24%)	664 (76%)	104 (68; 224)	53.2% (43.9; 60.9)
	No	444	164 (37%)	280 (63%)	692 (476; 836)[2]	
Type of chronic condition						
Asthma	Yes	139	26 (19%)	113 (81%)	86 (60; 204)	45.2% (-55.4; 80.7)
	No	130	37 (28%)	93 (72%)	737 (556; 898)[2]	
Lung disease	Yes	649	125 (19%)	524 (81%)	99 (63; 216)	44.5% (28.1; 57.1)
	No	440	128 (29%)	312 (71%)	723 (496; 846)[2]	
Cardiovascular disease	Yes	780	170 (22%)	610 (78%)	95 (63; 220)	58.0% (43.0; 69.1)
	No	503	179 (36%)	324 (64%)	723 (507; 845)[2]	
Hypertension	Yes	1161	258 (22%)	903 (78%)	102 (64; 220)	50.1% (29.0; 64.9)
	No	747	258 (35%)	489 (65%)	724 (519; 848)[2]	
Chronic liver disease	Yes	89	25 (28%)	64 (72%)	131 (66; 224)	58.2% (37.3; 72.2)
	No	107	46 (43%)	61 (57%)	719 (467; 878)[2]	
Renal disease	Yes	297	89 (30%)	208 (70%)	99 (66; 226)	44.3% (24.3; 59.0)
	No	203	82 (40%)	121 (60%)	732 (554; 885)[2]	
Type 2 diabetes	Yes	576	137 (24%)	439 (76%)	108 (67; 227)	40.9% (27.4; 51.9)
	No	355	123 (35%)	232 (65%)	718 (541; 882)[2]	
Immunodeficiency or cancer [3]	Yes	316	93 (29%)	223 (71%)	144 (60; 233)	46.6% (-24.6; 77.1)
	No	332	125 (38%)	207 (62%)	728 (534; 872)[2]	
Number of chronic conditions						
0-1[4]	Yes	383	103 (27%)	280 (73%)	134 (68; 228)	31.8% (18.2; 43.2)
	No	583	160 (27%)	423 (73%)	775 (648; 926)[2]	
2	Yes	488	95 (19%)	393 (81%)	107 (67; 221)	69.8% (64.7; 74.1)
	No	339	112 (33%)	227 (67%)	737 (543; 893)[2]	
≥3	Yes	762	180 (24%)	582 (76%)	100 (63; 220)	42.2% (33.8; 49.5)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
Weeks since BNT162b2 XBB vaccine dose						
2 to <30 wks	Yes	1146	193 (17%)	953 (83%)	77 (55; 120)	64.5% (56.6; 71.0)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
2 to <12 wks	Yes	660	105 (16%)	555 (84%)	59 (45; 71)	68.6% (56.0; 77.6)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
12 to <18 wks	Yes	212	28 (13%)	184 (87%)	96 (89; 107)	75.3% (68.4; 80.6)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
18 to <24 wks	Yes	101	20 (20%)	81 (80%)	145 (137; 155)	59.2% (43.9; 70.3)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
24 to <30 wks	Yes	173	40 (23%)	133 (77%)	194 (182; 203)	50.5% (35.8; 61.9)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
30 to <46 wks	Yes	487	185 (38%)	302 (62%)	250 (230; 272)	4.9% (-30.3; 30.7)
	No	1426	449 (31%)	977 (69%)	744 (566; 898)[2]	
Severity level[5]						
Hospital admission, no ICU, no IH death	Yes	1489	347 (23%)	1142 (77%)	110 (66; 223)	46.5% (31.9; 58.0)
	No	1304	408 (31%)	896 (69%)	747 (566; 898)[2]	
ICU admission, no IH death	Yes	29	4 (14%)	25 (86%)	77 (62; 215)	63.7% (23.8; 82.7)
	No	50	15 (30%)	35 (70%)	778 (695; 882)[2]	
In-hospital death	Yes	113	26 (23%)	87 (77%)	88 (62; 224)	57.8% (-15.4; 84.5)
	No	68	24 (35%)	44 (65%)	645 (525; 904)[2]	
ICU admission or IH death	Yes	142	30 (21%)	112 (79%)	86 (62; 216)	55.4% (21.3; 74.8)
	No	118	39 (33%)	79 (67%)	716 (555; 900)[2]	
Respiratory support level[6]						
None	Yes	284	69 (24%)	215 (76%)	114 (62; 226)	61.9% (46.1; 73.0)
	No	308	98 (32%)	210 (68%)	778 (623; 918)[2]	
Oxygen therapy	Yes	901	187 (21%)	714 (79%)	121 (68; 224)	50.5% (31.4; 64.2)
	No	596	187 (31%)	409 (69%)	737 (568; 899)[2]	
Non-invasive ventilation	Yes	174	34 (20%)	140 (80%)	97 (61; 216)	-38.3% (-88.4; -1.6)
	No	96	19 (20%)	77 (80%)	724 (479; 901)[2]	
Invasive mechanical ventilation	Yes	9	0 (0%)	9 (100%)	69 (61; 97)	
	No	10	3 (30%)	7 (70%)	722 (708; 786)[2]	
ECMO	Yes	0	0 (0%)	0 (0%)		
	No	1	1 (100%)	0 (0%)	519 (519; 519)[2]	
Length of stay						
LOS ≥ 2 days	Yes	1603	368 (23%)	1235 (77%)	107 (65; 223)	49.2% (40.7; 56.4)
	No	1379	436 (32%)	943 (68%)	744 (566; 899)[2]	
LOS ≥ 4 days	Yes	1296	295 (23%)	1001 (77%)	102 (64; 222)	50.4% (43.3; 56.6)
	No	1113	359 (32%)	754 (68%)	744 (566; 898)[2]	
LOS ≥ 7 days	Yes	692	137 (20%)	555 (80%)	88 (61; 210)	61.5% (51.8; 69.2)
	No	635	197 (31%)	438 (69%)	735 (563; 875)[2]	



Abbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IH, in-hospital; IQR, interquartile range; LOS, length of stay; N, number; VE, vaccine effectiveness

[1] Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, number of chronic conditions and receipt of influenza vaccine in the 12 months prior to current hospital admission.

[2] *'Never vaccinated' study participants were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season).*

[3] *The categories "Cancer" and "Immunodeficiency" among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having "Immunodeficiency or cancer" is provided as a composite.*

[4] *The categories "0" and "1" among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having "0–1" chronic conditions is provided as a composite.*

[5] *The categories "Hospital admission, no ICU, no IH death", "ICU admission, no IH death", and "In-hospital death" are mutually exclusive. An additional category is added to combine the latter two categories: "ICU admission or IH death".*

[6] *Respiratory support level, presented in ascending order of severity with the highest level used during hospital stay determine the category, are mutually exclusive: 1) none; 2) oxygen therapy (e.g., nasal cannula or mask); 3) non-invasive ventilation (support without endotracheal intubation such as high flow nasal oxygen, continuous or bi-level positive airway pressure); 4) invasive mechanical ventilation (support with endotracheal intubation); and 5) extracorporeal membrane oxygenation (ECMO).*

Figure 3. Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.



Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, number of chronic conditions and influenza vaccination status for the last 12 months. The tick marks on the x-axis of the figure indicate the time since the BNT162b2 XBB vaccine received by the SARI patients included in the analysis. The grey-shaded area corresponds to the 95% CI.

677 **Figure 4. Vaccine effectiveness against JN.1-related hospitalisation in**
678 **SARI patients who received at least one dose of BNT162b2 XBB vaccine**
679 **compared to patients who did not receive any dose of a COVID-19**
680 **vaccine in the 2023–2024 autumn/winter, with durability stratified by**
681 **age group.**

Strata	Exposure	Total, N	Test-positive cases: N (%)	Test-negative controls: N (%)	Days since last vaccine dose: Median (Q1; Q3)	VE (95% CI)[1]
Aged 18-64 years old						
Overall	Yes	166	35 (21%)	131 (79%)	106 (62; 226)	65.6% (55.5; 73.5)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
Weeks since BNT162b2 XBB vaccine dose						
2 to <30 wks	Yes	115	17 (15%)	98 (85%)	76 (48; 126)	77.2% (66.5; 84.5)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
2 to <12 wks	Yes	67	9 (13%)	58 (87%)	54 (34; 71)	80.7% (69.4; 87.8)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
12 to <18 wks	Yes	19	2 (11%)	17 (89%)	95 (90; 104)	85.0% (54.3; 95.1)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
18 to <24 wks	Yes	15	2 (13%)	13 (87%)	149 (138; 156)	76.3% (38.1; 91.0)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
24 to <30 wks	Yes	14	4 (29%)	10 (71%)	192 (182; 197)	40.5% (-86.4; 81.0)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
30 to <46 wks	Yes	51	18 (35%)	33 (65%)	245 (228; 272)	24.1% (-10.1; 47.7)
	No	525	153 (29%)	372 (71%)	791 (701; 916)[2]	
Aged ≥ 65 years old						
Overall	Yes	1467	343 (23%)	1124 (77%)	107 (65; 223)	44.9% (39.5; 49.7)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
Weeks since BNT162b2 XBB vaccine dose						
2 to <30 wks	Yes	1031	176 (17%)	855 (83%)	77 (56; 120)	63.5% (52.6; 71.8)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
2 to <12 wks	Yes	593	96 (16%)	497 (84%)	59 (46; 71)	68.1% (52.7; 78.5)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
12 to <18 wks	Yes	193	26 (13%)	167 (87%)	96 (89; 108)	74.9% (66.2; 81.4)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
18 to <24 wks	Yes	86	18 (21%)	68 (79%)	144 (137; 155)	56.4% (34.7; 70.9)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
24 to <30 wks	Yes	159	36 (23%)	123 (77%)	195 (182; 203)	49.8% (23.8; 67.0)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	
30 to <46 wks	Yes	436	167 (38%)	269 (62%)	250 (231; 272)	-1.8% (-48.4; 30.2)
	No	901	296 (33%)	605 (67%)	717 (510; 846)[2]	



682
683 *Abbreviations: N, number; VE, vaccine effectiveness*

684 *[1] Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, number of chronic conditions and receipt of*
685 *influenza vaccine 12 months prior to current hospital admission.*

686 *[2] 'Never vaccinated' study participants were excluded when calculating the median (IQR) of time since last vaccine dose in the*
687 *unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season).*

688

689

Figure 5. Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter, with durability stratified by number of chronic conditions.

Strata	Exposure	Total, N	Test-positive cases: N (%)	Test-negative controls: N (%)	Days since last vaccine dose: Median (Q1; Q3)	VE (95% CI)[1]
With 0-2 chronic conditions						
Overall	Yes	871	198 (23%)	673 (77%)	120 (67; 224)	53.6% (47.0; 59.4)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
Weeks since BNT162b2 XBB vaccine dose						
2 to <30 wks	Yes	602	98 (16%)	504 (84%)	79 (55; 132)	68.6% (62.3; 73.9)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
2 to <12 wks	Yes	340	52 (15%)	288 (85%)	59 (46; 72)	71.1% (61.7; 78.2)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
12 to <18 wks	Yes	103	13 (13%)	90 (87%)	94 (88; 106)	77.3% (61.0; 86.8)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
18 to <24 wks	Yes	61	11 (18%)	50 (82%)	146 (136; 155)	64.9% (37.7; 80.2)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
24 to <30 wks	Yes	98	22 (22%)	76 (78%)	193 (182; 201)	56.5% (45.2; 65.5)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
30 to <46 wks	Yes	269	100 (37%)	169 (63%)	250 (229; 275)	11.6% (-3.4; 24.5)
	No	922	272 (30%)	650 (70%)	759 (602; 912)[2]	
With ≥ 3 chronic conditions						
Overall	Yes	762	180 (24%)	582 (76%)	100 (63; 220)	42.2% (33.8; 49.5)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
Weeks since BNT162b2 XBB vaccine dose						
2 to <30 wks	Yes	544	95 (17%)	449 (83%)	74 (56; 111)	63.1% (49.1; 73.2)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
2 to <12 wks	Yes	320	53 (17%)	267 (83%)	59 (44; 69)	68.3% (45.6; 81.5)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
12 to <18 wks	Yes	109	15 (14%)	94 (86%)	97 (89; 109)	74.9% (68.5; 79.9)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
18 to <24 wks	Yes	40	9 (22%)	31 (78%)	144 (140; 153)	54.7% (9.6; 77.3)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
24 to <30 wks	Yes	75	18 (24%)	57 (76%)	197 (185; 204)	44.7% (20.0; 61.7)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	
30 to <46 wks	Yes	218	85 (39%)	133 (61%)	248 (232; 269)	-8.5% (-104.6; 42.4)
	No	504	177 (35%)	327 (65%)	710 (489; 834)[2]	



Abbreviations: N, number; VE, vaccine effectiveness

[1] Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, number of chronic conditions and receipt of influenza vaccine 12 months prior to current hospital admission.

[2] 'Never vaccinated' study participants were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season).